Psychedelics

Mindset Pharma to be Acquired by Otsuka Pharmaceutical

Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) announced that they have entered into a definitive arrangement agreement (the "Agreement") pursuant…

August 31, 2023

Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics

Mindset Pharma: Leaders in Next-Gen Psychedelics We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma…

July 11, 2023

Mindset Pharma: Approval for Phase II Clinical Trial, MSP-1014 for Treatment of Major Depressive Disorder

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced that it has received approval from the U.K. Medicines and…

June 22, 2023

Mindset Pharma: New Study Supports Non-Hallucinogenic Psychedelics

Recently, Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company specializing in next-generation psychedelics, announced the filing of…

June 15, 2023

Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds

Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to…

April 27, 2023

Capital 10X Growth Navigator: The Global Energy Crisis

In this edition of the Capital 10X Growth Navigator we examine the continuing global energy crisis and why we believe…

July 17, 2022

Growth Navigator: Copper Miners, Psychedelics & Crypto

Year-to-Date Commodity Heat Map Precious Metals vs. Crypto The strong tailwinds for cryptocurrencies (Bitcoin and Ethereum) have resulted in stagnant…

November 3, 2021